OpenAI buys Orchestra Bio to expand its drug research AI
OpenAI has taken over the startup Orchestra Bio, combining its Rosalind life sciences AI with Orchestra's platform. Financial terms of the purchase were not made public.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
OpenAI said it has acquired Orchestra Bio, a drug development platform startup, and is bringing its team and technology in-house. The company plans to combine Orchestra's platform with its Rosalind AI models for life sciences and its Rosalind Workbench tool, which helps researchers plan experiments and analyze results. The deal's terms were not disclosed.
Why it matters
The acquisition is aimed at using artificial intelligence to speed up drug development and help pharmaceutical teams coordinate research programs and manage delays.
Coverage
- OpenAI acquires startup Orchestra Bio to beef up its biotech business (techcrunch.com)
- OpenAI acquires drug tool to speed slow drug development workflows (interestingengineering.com)
- OpenAI Buys Orchestra Bio to Expand AI’s Role in Drug Development (citybiz.co)
- OpenAI Bets on Accelerating Drug Development Timelines with Orchestra Bio (pharmtech.com)
- OpenAI acquires Orchestra Bio in AI push for new drugs (TradingView)
- OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports (Investing.com)
More from Technology & AI
- Google expands Gemini's Personal Intelligence feature to cars
- Anthropic reports $16.3 billion first-half revenue in filing
- Students nationwide stage walkouts against artificial intelligence
- HPE sends AI computer to Moon on Astrolab rover
- OpenAI expands ChatGPT advertising with new formats and lower prices
- Anthropic and Musk pledge shares as OpenAI races to raise $30 billion